# Gossamer Bio, Inc.

Gossamer Bio, Inc. is a public company listed on Nasdaq as GOSS, headquartered in San Diego, CA, United States.

## Company overview

- **Legal name:** Gossamer Bio, Inc.
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** San Diego, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **Ticker:** Nasdaq: GOSS
- **SEC CIK:** 0001728117

## About

Gossamer Bio, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001728117, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-03-17, it reported annual revenue of USD 48,471,000; net income of USD -170,370,000; total assets of USD 172,249,000 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $48.5M (USD 48,471,000)
- **Net income:** -$170.4M (USD -170,370,000)
- **Total assets:** $172.2M (USD 172,249,000)
- **Cash and equivalents:** $37.7M (USD 37,732,000)
- **Operating cash flow:** -$171.3M (USD -171,266,000)

### FY2024 (period ended 2024-12-31)

- **Revenue:** $114.7M (USD 114,701,000)
- **Net income:** -$56.5M (USD -56,528,000)
- **Total assets:** $315.3M (USD 315,292,000)
- **Cash and equivalents:** $46.1M (USD 46,074,000)
- **Operating cash flow:** -$3.5M (USD -3,468,000)

### FY2023 (period ended 2023-12-31)

- **Net income:** -$179.8M (USD -179,817,000)
- **Total assets:** $311.9M (USD 311,916,000)
- **Cash and equivalents:** $32.1M (USD 32,109,000)
- **Operating cash flow:** -$159.2M (USD -159,158,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** -$229.4M (USD -229,378,000)
- **Total assets:** $272.4M (USD 272,450,000)
- **Cash and equivalents:** $112.0M (USD 111,973,000)
- **Operating cash flow:** -$187.0M (USD -187,032,000)

## Recent SEC filings

- Form 8-K — filed 2026-09-28 — period 2026-09-25 — 8-K
- Form 8-K — filed 2026-09-23 — period 2026-09-23 — 8-K
- Form DEF 14A — filed 2026-09-16 — period 2026-10-27 — DEF 14A
- Form 8-K — filed 2026-09-16 — period 2026-09-16 — 8-K
- Form 8-K — filed 2026-09-11 — period 2026-09-10 — 8-K
- Form 8-K — filed 2026-09-09 — period 2026-09-09 — 8-K
- Form 8-K — filed 2026-09-03 — period 2026-09-03 — 8-K
- Form 8-K — filed 2026-08-26 — period 2026-08-24 — 8-K
- Form 8-K — filed 2026-08-21 — period 2026-08-20 — 8-K
- Form 8-K — filed 2026-08-13 — period 2026-08-13 — 8-K
- Form 10-Q — filed 2026-08-13 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-07-27 — period 2026-07-23 — 8-K

---

Updated: 2026-10-23T05:02:54.863002+00:00

Canonical page: https://altss.com/profile/gossamer-bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology